Publications by authors named "Hugues Dolgos"

Claim this Profile
T
Translational strategies in drug development for knee osteoarthritis.
Kyra J Cowan, Kerstin Kleinschmidt-Dörr, Anne Gigout, Flavie Moreau, Jeff Kraines, Hugues Dolgos

Drug Discov Today· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies.
Sheila Annie Peters, Carl Petersson, Andree Blaukat, Joern-Peter Halle, Hugues Dolgos

Drug Discov Today· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of volume of distribution in humans: analysis of eight methods and their application in drug discovery.
Carl Petersson, Orestis Papasouliotis, Marc Lecomte, Lassina Badolo, Hugues Dolgos

Xenobiotica· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Role of Solubility in Oral Absorption of Poorly Water-Soluble Drugs Using Physiologically-Based Pharmacokinetic Modeling.
Christina Fink, Dajun Sun, Knut Wagner, Melanie Schneider, Holger Bauer, Hugues Dolgos

Clin Pharmacol Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them.
Sheila Annie Peters, Hugues Dolgos

Clin Pharmacokinet· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide.
Christian Lüpfert, Martin Dyroff, Oliver von Richter, Dieter Gallemann, Samer El Bawab, Hugues Dolgos

CPT Pharmacometrics Syst Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of methods for the prediction of human clearance from hepatocyte intrinsic clearance for a set of reference compounds and an external evaluation set.
Tetsuo Yamagata, Ugo Zanelli, Dieter Gallemann, Dominique Perrin, Hugues Dolgos

Xenobiotica· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative evaluation of models to predict human intestinal metabolism from nonclinical data.
Estelle Yau, Carl Petersson, Hugues Dolgos, Sheila Annie Peters

Biopharm Drug Dispos· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo drug disposition of cilengitide in animals and human.
Hugues Dolgos, Achim Freisleben, Elmar Wimmer, Holger Scheible, Friedrich Krätzer

Pharmacol Res Perspect· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational Medicine Guide transforms drug development processes: the recent Merck experience.
Hugues Dolgos, Mark Trusheim, Dietmar Gross, Joern-Peter Halle, Janet Ogden

Drug Discov Today· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time- and NADPH-dependent inhibition of cytochrome P450 3A4 by the cyclopentapeptide cilengitide: significance of the guanidine group and accompanying spectral changes.
Mirza Bojić, Luca Barbero, Hugues Dolgos, Achim Freisleben, Dieter Gallemann

Drug Metab Dispos· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human.
Holger Scheible, Marc Laisney, Elmar Wimmer, Ana Javornik, Hugues Dolgos

Xenobiotica· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development.
Fredrik H Karlsson, Salim Bouchene, Constanze Hilgendorf, Hugues Dolgos, Sheila Annie Peters

Drug Metab Dispos· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development.
Sheila Annie Peters, Patricia E Schroeder, Nagdeep Giri, Hugues Dolgos

Drug Metab Dispos· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.
Richard A Thompson, Emre M Isin, Yan Li, Lars Weidolf, Ken Page, Hugues Dolgos

Chem Res Toxicol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The right compound in the right assay at the right time: an integrated discovery DMPK strategy.
Peter Ballard, Patrick Brassil, Khanh H Bui, Hugues Dolgos, Carl Petersson

Drug Metab Rev· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development.
Richard A Thompson, Emre M Isin, Yan Li, Richard Weaver, Lars Weidolf, Hugues Dolgos

Chem Biol Interact· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
Dieter Gallemann, Elmar Wimmer, Constance C Höfer, Achim Freisleben, Markus Fluck, Hugues Dolgos

Drug Metab Dispos· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
Sheila Annie Peters, Anna-Lena Ungell, Hugues Dolgos

Curr Opin Drug Discov Devel· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions.
Roslyn S Thelingwani, Simbarashe P Zvada, Hugues Dolgos, Anna-Lena B Ungell, Collen M Masimirembwa

Drug Metab Dispos· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
Johan Gabrielsson, Hugues Dolgos, Per-Göran Gillberg, Ulf Bredberg, Bert Benthem

Drug Discov Today· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro.
Lysiane Richert, Gregor Tuschl, Catherine Viollon-Abadie, Nadège Blanchard, Alexandre Bonet, Hugues Dolgos

Drug Metab Dispos· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
Sonja Krösser, Roland Neugebauer, Hugues Dolgos, Markus Fluck, Karl-Ludwig Rost

Eur J Clin Pharmacol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis